Immunotech Biopharm Ltd. announced unaudited consolidated earnings results for the six months ended June 30, 2021. For the period, the company reported loss and total comprehensive expenses for the period of RMB 147,604,000 against RMB 174,067,000 a year ago. Basic and diluted loss per share was RMB 0.29 against RMB 0.46 a year ago.